These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

671 related items for PubMed ID: 19171799

  • 21. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance.
    Shallom SJ, Gardina PJ, Myers TG, Sebastian Y, Conville P, Calhoun LB, Tettelin H, Olivier KN, Uzel G, Sampaio EP, Holland SM, Zelazny AM.
    J Clin Microbiol; 2013 Sep; 51(9):2943-9. PubMed ID: 23804391
    [Abstract] [Full Text] [Related]

  • 22. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns.
    Kim HY, Kim BJ, Kook Y, Yun YJ, Shin JH, Kim BJ, Kook YH.
    Microbiol Immunol; 2010 Jun; 54(6):347-53. PubMed ID: 20536733
    [Abstract] [Full Text] [Related]

  • 23. New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group.
    Shallom SJ, Moura NS, Olivier KN, Sampaio EP, Holland SM, Zelazny AM.
    J Clin Microbiol; 2015 Nov; 53(11):3430-7. PubMed ID: 26269619
    [Abstract] [Full Text] [Related]

  • 24. Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm(41).
    Carvalho NFG, Pavan F, Sato DN, Leite CQF, Arbeit RD, Chimara E.
    J Antimicrob Chemother; 2018 Apr 01; 73(4):862-866. PubMed ID: 29272470
    [Abstract] [Full Text] [Related]

  • 25. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents.
    Yoshida S, Tsuyuguchi K, Suzuki K, Tomita M, Okada M, Hayashi S, Iwamoto T, Saito H.
    Int J Antimicrob Agents; 2013 Sep 01; 42(3):226-31. PubMed ID: 23850022
    [Abstract] [Full Text] [Related]

  • 26. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.
    Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ.
    J Antimicrob Chemother; 2005 Feb 01; 55(2):170-7. PubMed ID: 15590712
    [Abstract] [Full Text] [Related]

  • 27. In Vitro Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Mycobacterium abscessus Complex.
    Cheng A, Tsai YT, Chang SY, Sun HY, Wu UI, Sheng WH, Chen YC, Chang SC.
    Antimicrob Agents Chemother; 2019 Apr 01; 63(4):. PubMed ID: 30670428
    [Abstract] [Full Text] [Related]

  • 28. Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital.
    Chew KL, Cheng JWS, Hudaa Osman N, Lin RTP, Teo JWP.
    J Med Microbiol; 2017 Oct 01; 66(10):1443-1447. PubMed ID: 28874233
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Lack of association between rrl and erm(41) mutations and clarithromycin resistance in Mycobacterium abscessus complex.
    Carneiro MDS, Nunes LS, David SMM, Barth AL.
    Mem Inst Oswaldo Cruz; 2017 Nov 01; 112(11):775-778. PubMed ID: 29091138
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prevalence of resistance to macrolides and aminoglycosides in Mycobacterium avium, M. abscessus, and M. chelonae identified in the Laboratorio Nacional de Referencia of Colombia from 2018 to 2022.
    Llerena C, Valbuena YA, Zabaleta AP, García AN.
    Biomedica; 2024 May 30; 44(2):182-190. PubMed ID: 39088528
    [Abstract] [Full Text] [Related]

  • 36. In vitro activity of telithromycin and quinupristin/dalfopristin against methicillin-resistant coagulase-negative staphylococci with defined resistance genotypes.
    Novotná G, Spízek J, Janata J.
    Folia Microbiol (Praha); 2007 May 30; 52(6):593-9. PubMed ID: 18450221
    [Abstract] [Full Text] [Related]

  • 37. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.
    Bemer-Melchior P, Juvin ME, Tassin S, Bryskier A, Schito GC, Drugeon HB.
    Antimicrob Agents Chemother; 2000 Nov 30; 44(11):2999-3002. PubMed ID: 11036012
    [Abstract] [Full Text] [Related]

  • 38. Molecular characterization of Mycobacterium abscessus subspecies isolated from patients attending an Italian Cystic Fibrosis Centre.
    Teri A, Sottotetti S, Arghittu M, Girelli D, Biffi A, D'Accico M, Daccò V, Gambazza S, Pizzamiglio G, Trovato A, Tortoli E, Colombo C, Cariani L.
    New Microbiol; 2020 Jul 30; 43(3):127-132. PubMed ID: 32656572
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.